Anavex Life Sciences Corp (AVXL)

[falconer66a]

US and World Alzheimer’s Drug Market

“If Alzheimer's prevalence estimates were to include this "preclinical stage" before symptoms arise, the number of those affected would more than double from the current estimate of 5.4 million Americans, the study stated.”

https://eurekalert.org/pub_releases/2017-06/uosc-rd061217.php

So, approximately 11 million of the 318 million people living in the US will develop Alzheimer’s Disease. That’s, presently, approximately 3.4 percent. (Likely to increase as we baby boomers enter our old age.)

If that holds for the world’s population (approximately 7.5 billion this year), that’s about 250 million.

It would not be unreasonable, then to project an approximate 100 million Alzheimer’s cases in the Western, developed world (with health insurance or government health care to pay for Anavex 2-73 treatments).

If Anavex were to clear (after taxes, costs, etc.) just annually $10 per patient, that’s a profit of $1 billion.

Per-patient profits more likely would in the, say, $100 range (or much higher), yielding at least a $10 billion annual profit (flowing down in dividends to AVXL shareholders).

Figure it out yourself. Currently, Anavex has 41.3 million shares in the hands of shareholders.

I have not crunched any future Parkinson’s, amyolateral sclerosis, or other Anavex-treated disease numbers.